Reviva Pharmaceuticals Holdings Inc. Total Liabilities
Reviva Pharmaceuticals Holdings Inc. total liabilities. Based on the latest financial reports, Reviva Pharmaceuticals Holdings Inc. (RVPH) has total liabilities worth $5.93 Trillion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Reviva Pharmaceuticals Holdings Inc. asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Reviva Pharmaceuticals Holdings Inc. (2018–2025)
Total liabilities of Reviva Pharmaceuticals Holdings Inc. from 2018 to 2025. This chart illustrates how Reviva Pharmaceuticals Holdings Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Reviva Pharmaceuticals Holdings Inc. Competitors by Total Liabilities
The table below lists competitors of Reviva Pharmaceuticals Holdings Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Citra Nusa Holdings Bhd
KLSE:5104
|
Malaysia | RM14.65 Million |
|
Argentina Lithium & Energy Corp
V:LIT
|
Canada | CA$4.76 Million |
|
Identi Healthcare Ltd
TA:IDNT
|
Israel | ILA3.92 Million |
|
GIGLIO.COM S.P.A. O.N.
F:5JR0
|
Germany | €8.43 Million |
|
Maschinenfabrik HEID AG
VI:HED
|
Austria | €54.61K |
|
J-Long Group Limited
NASDAQ:JL
|
USA | $1.43 Million |
|
Encres Dubuit SA
PA:ALDUB
|
France | €4.43 Million |
|
Rossi Residencial S.A
SA:RSID3
|
Brazil | R$1.21 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Reviva Pharmaceuticals Holdings Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Reviva Pharmaceuticals Holdings Inc. balance sheet assets.
Liquidity & Leverage Metrics
Reviva Pharmaceuticals Holdings Inc. Total Liabilities Ratios Explained
Reviva Pharmaceuticals Holdings Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Reviva Pharmaceuticals Holdings Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Reviva Pharmaceuticals Holdings Inc. (2018–2025)
The table below shows the annual total liabilities of Reviva Pharmaceuticals Holdings Inc. from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.28 Million | -50.47% |
| 2024-12-31 | $14.69 Million | -18.30% |
| 2023-12-31 | $17.98 Million | +70.78% |
| 2022-12-31 | $10.53 Million | +287.46% |
| 2021-12-31 | $2.72 Million | -17.56% |
| 2020-12-31 | $3.30 Million | -51.62% |
| 2019-12-31 | $6.81 Million | +11.96% |
| 2018-12-31 | $6.09 Million | -- |
About Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, s… Read more